Search results for "benzoxazine"

showing 10 items of 78 documents

Adolescent Exposure to the Synthetic Cannabinoid WIN 55212-2 Modifies Cocaine Withdrawal Symptoms in Adult Mice

2017

Chronic cannabinoid consumption is an increasingly common behavior among teenagers and has been shown to cause long-lasting neurobehavioral alterations. Besides, it has been demonstrated that cocaine addiction in adulthood is highly correlated with cannabis abuse during adolescence. Cocaine consumption and subsequent abstinence from it can cause psychiatric symptoms, such as psychosis, cognitive impairment, anxiety, and depression. The aim of the present research was to study the consequences of adolescent exposure to cannabis on the psychiatric-like effects promoted by cocaine withdrawal in adult mice. We pre-treated juvenile mice with the cannabinoid CB1 receptor agonist WIN 55212-2 (WIN)…

MalecannabisCannabinoid receptormedicine.medical_treatment0302 clinical medicineCocaineDopamine Uptake InhibitorsReceptor Cannabinoid CB1Spectroscopymedia_commoncocaine withdrawalBehavior Animalbiologyadolescence; cannabis; WIN 55212-2; cocaine withdrawal; miceGeneral MedicineSubstance Withdrawal SyndromeComputer Science ApplicationsHindlimb SuspensionElevated plus mazePsychosismedicine.medical_specialtymiceMorpholinesmedia_common.quotation_subjectNaphthalenesArticleCatalysisInorganic ChemistryCocaine-Related Disorders03 medical and health sciencesMemoryInternal medicinemedicineAnimalsWIN 55212-2Physical and Theoretical ChemistryPsychiatryMolecular BiologyCannabinoid Receptor Agonistsbusiness.industryAddictionOrganic ChemistryAbstinencemedicine.diseasebiology.organism_classificationBenzoxazines030227 psychiatryEndocrinologyAnxiogenicExploratory BehavioradolescenceCannabisCannabinoidbusiness030217 neurology & neurosurgeryInternational Journal of Molecular Sciences
researchProduct

Nicotinic cholinoceptive neurons of the frontal cortex are reduced in Alzheimer's disease.

1991

The cellular distribution of nicotinic acetylcholine receptors was studied in the frontal cortex (area 10) of 1) Alzheimer patients and compared to 2) age-matched and 3) middle-aged controls using the monoclonal antibody WF 6 and an immunoperoxidase protocol. Statistical analysis revealed significant differences between the number of labeled neurons among all three groups tested (middle-aged controls greater than aged controls greater than Alzheimer cases). No differences were seen for cresyl violet-stained samples. These findings underline that the nicotinic receptor decrease found with radioligand binding may reflect a postsynaptic in addition to a presynaptic component.

Malemedicine.medical_specialtyAgingImmunocytochemistryBiologyReceptors NicotinicImmunoenzyme TechniquesPostsynaptic potentialAlzheimer DiseaseInternal medicineOxazinesmedicineHumansReceptorAcetylcholine receptorAgedNeuronsImmunoperoxidaseGeneral NeuroscienceAntibodies Monoclonalmedicine.diseaseBenzoxazinesFrontal Lobemedicine.anatomical_structureEndocrinologyNicotinic agonistCerebral cortexFemaleNeurology (clinical)Geriatrics and GerontologyAlzheimer's diseaseDevelopmental BiologyNeurobiology of aging
researchProduct

Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study

2016

Rüdiger Sauer,1 Michaela Hänsel,2 Roland Buhl,3 Roman A Rubin,4 Marcel Frey,5 Thomas Glaab2,3 1Lung Centre Ulm, Ulm, Germany; 2Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany; 3Pulmonary Department, Mainz University Hospital, Mainz, Germany; 4Pulmonary Specialist Practice, Wiesbaden, Germany; 5Biometrics, Alcedis GmbH, Gießen, Germany Background: Maintaining and improving physical functioning is key to mitigating the cycle of deconditioning associated with chronic obstructive pulmonary disease (COPD). We evaluated the impact of free combination of the long-acting anticholinergic tiotropium plus the long-acting β2-agonist ol…

Malereal-worldTime FactorsnoninterventionalHealth StatusSeverity of Illness IndexCholinergic AntagonistsPulmonary Disease Chronic Obstructivechemistry.chemical_compound0302 clinical medicinetiotropiumDeconditioningPhysical functioningSurveys and QuestionnairesProspective Studies030212 general & internal medicineLungOriginal ResearchCOPDOlodaterolGeneral MedicineTiotropium bromideMiddle AgedBronchodilator AgentsDrug CombinationsTreatment OutcomeFemalemedicine.drugmedicine.medical_specialtymedicine.drug_classInternational Journal of Chronic Obstructive Pulmonary Diseasechronic obstructive pulmonary disease03 medical and health sciencesAdministration InhalationSeverity of illnessmedicineAnticholinergicphysical functioningHumansTiotropium BromideIntensive care medicineAdrenergic beta-2 Receptor AgonistsAgedolodaterolbusiness.industryNebulizers and VaporizersRecovery of Functionmedicine.diseaseBenzoxazines030228 respiratory systemchemistryPhysical therapyObservational studybusinessInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Efavirenz alters mitochondrial respiratory function in cultured neuron and glial cell lines.

2015

Abstract Background The NNRTI efavirenz is among the most widely employed antiretroviral drugs. Although it is considered safe, efavirenz has been linked with several adverse effects including neurological manifestations, which appear in the majority of the patients on efavirenz-containing regimens. The molecular mechanisms responsible for these manifestations are not understood, but mounting evidence points to altered brain bioenergetics. Methods We evaluated the effect of short-term efavirenz treatment on the mitochondrial respiratory function of cultured glioblastoma and differentiated neuroblastoma cell lines using a Seahorse Extracellular Flux Analyzer. Results Incubation with efaviren…

Microbiology (medical)CyclopropanesCell typeEfavirenzCell RespirationBiologyPharmacologyMitochondrionCell Linechemistry.chemical_compoundAdenosine TriphosphateRespirationExtracellularmedicineHumansPharmacology (medical)Respiratory functionPharmacologyNeuronsNeurotoxicityvirus diseasesmedicine.diseaseVirologyBenzoxazinesMitochondriaInfectious Diseasesmedicine.anatomical_structurechemistryAnti-Retroviral AgentsAlkynesNeurogliaEnergy MetabolismNeurogliaThe Journal of antimicrobial chemotherapy
researchProduct

Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz.

2014

Objectives Growing evidence associates the non-nucleoside reverse transcriptase inhibitor efavirenz with several adverse events. Newer antiretrovirals, such as the integrase inhibitor raltegravir, the non-nucleoside reverse transcriptase inhibitor rilpivirine and the protease inhibitor darunavir, claim to have a better toxicological profile than efavirenz while producing similar levels of efficacy and virological suppression. The objective of this study was to determine the in vitro toxicological profile of these three new antiretrovirals by evaluating their effects on the mitochondrial and cellular parameters altered by efavirenz in hepatocytes and neurons. Methods Hep3B cells and primary …

Microbiology (medical)CyclopropanesEfavirenzAnti-HIV AgentsIntegrase inhibitorBiologyMitochondrionPharmacologychemistry.chemical_compoundCell Line TumorRaltegravir PotassiumDrug Resistance ViralNitrilesmedicineAnimalsHumansPharmacology (medical)DarunavirCells CulturedDarunavirPharmacologyNeuronsSulfonamidesReverse-transcriptase inhibitorRilpivirinemedicine.diseaseRaltegravirPyrrolidinonesBenzoxazinesMitochondriaRatsMitochondrial toxicityInfectious DiseasesPyrimidineschemistryRilpivirineAlkynesHepatocytesReverse Transcriptase Inhibitorsmedicine.drugThe Journal of antimicrobial chemotherapy
researchProduct

Efavirenz and the CNS: what we already know and questions that need to be answered

2015

The NNRTI efavirenz has long been one of the most frequently employed antiretroviral drugs in the multidrug regimens used to treat HIV infection, in accordance with its well-demonstrated antiretroviral efficacy and favourable pharmacokinetics. However, growing concern about its adverse effects has sometimes led to efavirenz being replaced by other drugs in the initial treatment selection or to switching of therapy to efavirenz-free regimens in experienced patients. Neurological and neuropsychiatric reactions are the manifestations most frequently experienced by efavirenz-treated patients and range from transitory effects, such as nightmares, dizziness, insomnia, nervousness and lack of conc…

Microbiology (medical)DrugCentral Nervous SystemCyclopropanesPsychosismedicine.medical_specialtyEfavirenzAnti-HIV Agentsmedia_common.quotation_subjectHIV InfectionsPolymorphism Single Nucleotidechemistry.chemical_compoundimmune system diseasesCentral Nervous System DiseasesAntiretroviral Therapy Highly ActivemedicineAnimalsCytochrome P-450 Enzyme InhibitorsHumansPharmacology (medical)Adverse effectIntensive care medicineSuicidal ideationmedia_commonPharmacologybusiness.industryNeurotoxicityvirus diseasesmedicine.diseaseBenzoxazinesCytochrome P-450 CYP2B6Disease Models AnimalInfectious DiseaseschemistryPharmacogeneticsAlkynesReverse Transcriptase Inhibitorsmedicine.symptomCNSEfavirenzbusinessNeurocognitivePharmacogenetics
researchProduct

Simultaneous confocal laser endomicroscopy and chromoendoscopy with topical cresyl violet

2009

Background Confocal laser endomicroscopy (CLE) has been shown to reliably predict histology during ongoing endoscopy. To unmask lesions for CLE, chromoendoscopy has been mandated. Usually fluorescein then serves as a contrast agent for CLE, but it does not allow direct nuclear visualization, must be injected, leads to a transient skin discoloration, and may have allergic side effects. Objective To establish a single topical dye, cresyl violet (CV), for simultaneous chromoendoscopy and in vivo CLE of the lower GI tract. Design Animal preclinical study, prospective clinical trial. Setting Mainz University Clinic (tertiary care center). Patients, Methods, and Interventions To establish the sta…

Pathologymedicine.medical_specialtyColonAdministration TopicalConfocalPilot ProjectsEndoscopy Gastrointestinallaw.inventionChromoendoscopyDiagnosis DifferentialMicechemistry.chemical_compoundCresyl violetIleumIn vivoConfocal microscopylawOxazinesEndomicroscopyAnimalsHumansMedicineRadiology Nuclear Medicine and imagingIntestinal MucosaFluoresceinColoring AgentsMicroscopy Confocalbusiness.industryGastroenterologyReproducibility of ResultsHistologyMiddle AgedBenzoxazinesIleal NeoplasmsDisease Models AnimalchemistryColonic NeoplasmsFemalebusinessCarcinoma in SituGastrointestinal Endoscopy
researchProduct

The effect of cannabinoid receptor agonist WIN 55,212-2 on anxiety-like behavior and locomotion in a genetic model of absence seizures in the elevate…

2022

GAERS and NEC rats were treated with cannabinoid 1/2 receptor agonist WIN 55,212-2 2 mg/kg and tested on the Elevated Plus-Maze

PharmacologyCannabinoid Receptor AgonistsModels GeneticMorpholinesNECWIN 55212-2 2AnxietyNaphthalenesSettore BIO/09 - FisiologiaBenzoxazinesRatsElevated Plus Maze TestPsychiatry and Mental healthEpilepsy AbsenceSeizuresPhysiology (medical)GAERSAnimalsPharmacology (medical)Elevated Plus-MazeRats WistarLocomotionCNS neurosciencetherapeutics
researchProduct

Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials.

2018

Abstract Background An extensive clinical trial program supports the efficacy and safety of tiotropium/olodaterol in chronic obstructive pulmonary disease (COPD). We examined the safety of tiotropium/olodaterol compared with tiotropium in a large population of patients, focusing on cardiovascular and respiratory events. Methods Patients (n = 9942) who received once-daily tiotropium/olodaterol 5/5 μg or tiotropium 5 μg (via Respimat®) in TONADO 1 & 2 and DYNAGITO were included. The number of patients and exposure-adjusted rate of events are presented for adverse events (AEs), serious AEs (SAEs), AEs leading to discontinuation, and cardiovascular and respiratory events. Findings Fewer patient…

Pulmonary and Respiratory MedicineMaleRiskmedicine.medical_specialtyTime FactorsRate ratiolaw.invention03 medical and health scienceschemistry.chemical_compoundPulmonary Disease Chronic Obstructive0302 clinical medicineRandomized controlled triallawCentral Nervous System DiseasesRisk FactorsInternal medicinemedicineHumans030212 general & internal medicineTiotropium BromideAdverse effectRandomized Controlled Trials as TopicCOPDbusiness.industryIncidenceOlodaterolmedicine.diseasehumanitiesrespiratory tract diseasesDiscontinuationBenzoxazinesClinical trialDrug Combinations030228 respiratory systemchemistryCardiovascular DiseasesFemaleSafetybusinesshuman activitiesMaceRespiratory medicine
researchProduct

The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD

2020

This exploratory, randomised, double-blind, double-dummy, multicentre, cross-over study explored the effect of 6 weeks of treatment with tiotropium/olodaterol (T/O) versus fluticasone propionate/salmeterol (F/S) on left ventricular filling in patients with chronic obstructive pulmonary disease with functional residual capacity (FRC) >120% predicted and postbronchodilator improvement of FRC ≥7.5%. Overall, 76 patients were randomised across nine sites. Treatment with T/O or F/S increased left ventricular end-diastolic volume index from baseline (adjusted mean change: T/O: 2.317 mL/m2, F/S: 2.855 mL/m2), with no statistically significant difference between treatments. However, T/O resulted…

Pulmonary and Respiratory Medicinemedicine.medical_specialtylcsh:MedicineFluticasone propionatePulmonary Disease Chronic Obstructive03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFunctional residual capacityInternal medicinemedicineHumansMulticenter Studies as TopicPlethysmographIn patient1506030212 general & internal medicineTiotropium BromideLunginhaler devicesRandomized Controlled Trials as Topiclcsh:RC705-779COPDCross-Over Studiesbusiness.industrylcsh:ROlodaterollcsh:Diseases of the respiratory systemrespiratory systemmedicine.diseaseFluticasone-Salmeterol Drug CombinationBenzoxazinesBronchodilator Agentsrespiratory tract diseasesrespiratory measurement030228 respiratory systemchemistryPerspectiveCardiologyCOPD pharmacologySalmeterolVentricular fillingbusinessmedicine.drugBMJ Open Respiratory Research
researchProduct